In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Roger Boshes
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Roger Boshes

First Name:Roger
Last Name:Boshes
Advanced Degrees:MD. PhD
Affiliation:JC Corrigan Mental Health Center, Harvard Medical School
Street Address 1:John C Corrigan Mental Health Center
Street Address 2:49 Hillside Street
City:Fall River
Zip/Postal Code:02720
Phone:508 574 8456
Fax:508 235 7346
Email Address:
(view policy) 
Member reports no financial or other potential conflicts of interest. [Last Modified: 10 August 2013]
View all comments by Roger Boshes
Clinical Interests:
Drug abuse, Autism spectrum disorders (pervasive developmental disorders), Schizophrenia
Research Focus:
Genetics, Pharmacology
Work Sector(s):
Community Mental Health Center
Reasearcher Bio
I have a PhD in genetics from the University of Chicago. I did a post doc in the Dept. of Mol. Biophysics and Biochem at Yale and then worked at Yale Medical School on amelanotic and melanotic melanoma. I was mentored at Mass Mental Health Center by Carl Salzman MD, worked for John Davis at Univ of Illinois, and then returned to Boston where I worked with Ross Baldessarini MD and Bruce Cohen MD, PhD. I am interested in both the genetics and treatment of patients with schizophrenia.
Top Papers
Wikswo, M. A., McGuire, J. S., Shansky, J. E., & Boshes, R. A. (1977), Nuclear Nonhistone proteins from murine melanomacells: II changes following exposure to MSH. Journal of Investigative Dermatology, 69, 516-520.

Festa, R., Meadows, A., Boshes, R. A. (1979), Leukemia in a black child with Bloom's Syndrome: Somatic recombination as a possible mechanism for neoplasia. Cancer, 44, 1507-1510.

Boshes, R. A., Manschreck, T. M., Desrosiers, J., Candela, S. F., & Hanrahan-Boshes, M.(2001), Initiation of clozapine therapy in a patient with pre-existing leukopenia: A discussion of the rationale of current treatment options. Annals of Cliniclal Psychiatry: 13(4), 233-237.

Boshes, R. A., Manschreck, T. M. (2002), Review of antipsychotic medication administration: A proposal of intermittent dosing. Schizophrenia Bulletin, 28(2), 203-222.

Manschreck, T. M., Boshes, R. A. The CATIE Trial: Results, Impact, Controversy. Harvard Review of Psychiatry, 15, 245-258.

Boshes, R. A., Manschreck, T. M., & Konigsberg, K. (2012), Genetics of the schizophrenias: A model accounting for their persistence and myriad of phenotypes. Harvard Review of Psychiatry, 20(3), 119-129.
What are the top three papers (not yours) you have read recently?
Castner, S. A., Williams, G. V., Goldman-Rakic, P. S. (2000), Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science, 287, 2020-2022.

Samaha, A.-H., Reckless, G. E., Seeman, P., Diwan, M., Nobrega, J. N. & Kapur, S. (2008), Less is more: Antipsychotic drug effects are greater with transient rather than continuous delievery. Biological Psychiatry, 64, 145-152.

Remington, G., Seeman, P., Feingold, A., Mann, S., Shammi, C. & Kaopur, S. (2010),"Extended" antipsychotic dosing in the maintenance treatment of schizophrnia: A double-blind, placebo-controlled trial.Journal of Clinical Psychiatry, 71, 1-7.
If resources were not limited, what research projects would you pursue?
Efficacy of extended/intermittent dosing of antipsychotic agents to improve or, at least, maintain outcome, reduce costs, metabolic side effects and possible minimize cognitive damage.
What is your leading hypothesis?
We do not understand how antipsychotic drugs work or how to administer them.
Moreover, we do not know anything about how to match patients with the most effective medication
What piece of missing evidence would help prove it?
See the grant I am writing
What is your fallback position?
Resubmit grant or look for another source of funding

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright